Cogstate Ltd (ASX:CGS)

$1.58

right-arrow Created with Sketch. -0.14 (-8.16%)
MCAP $297.2M
Last trade 15.42pm 27/01/2022 20mins delayed

Latest Announcements

21/01/2022 Price SensitivePSCGSCogstate Ltd
870
MCap
21/01/2022 Price SensitivePSCGSCogstate Ltd
23/12/2021CGSCogstate Ltd
23/12/2021CGSCogstate Ltd
21/12/2021CGSCogstate Ltd
03/12/2021 Price SensitivePSCGSCogstate Ltd
03/12/2021CGSCogstate Ltd
03/12/2021CGSCogstate Ltd

Company Overview

Cogstate Ltd is an Australia-based neuroscience technology company. The Company provides computerized cognitive tests across various domains and support electronic clinical outcome assessment (eCOA) solutions. The Company's segment includes Clinical trials, Healthcare and Research. In the Clinical trials segment, the Company's technology and associated services are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. In the Healthcare segment, the technology and associated services are being developed as a tool for primary care physicians to assess cognitive decline. Research segment offers various research studies and academic collaborations across various indication of diseases.

CGS in the news

Neuroscience technology company Cogstate (CGS), has achieved an additional $19.1 million of…
Cognition researchers Cogstate has licensed its technology to Japanese pharmaceutical company EisaiThe…

Search Previous Announcements